Ticker brief · 2026-10-18

RXRX RECURSION PHARMACEUTICALS-A

Sanofi validation strengthens RXRX bulls as discounted financing tests conviction

Consumer, Non-cyclical · Biotechnology

Lean: bullish
last close
$3.70
1 day
+3.4%
14 days
-15.1%
mkt cap
$2.0B
signals 14d
120
authors 14d
53
crowd 14d
+0.2σ

RXRX sentiment is bullish, with stronger-credibility sources emphasizing platform potential and company developments, but no demonstrated smart-money accumulation. The late-week shift was from thematic AI-biotech enthusiasm to Sanofi validation and favorable clinical reports alongside a $200M offering at $3.25, followed by Morgan Stanley raising its target to $5.90 from $5.30 while retaining Equal Weight. High short interest and trimming near 4.20-4.25 frame a volatile catalyst trade; the bullish narrative runs against the stack's October 6 SHORT, which recorded ret_pct of 3.94.

BULL CAMP9 claims

Bulls see Recursion becoming an AI drug-discovery infrastructure platform, with Sanofi's option exercise and favorable clinical reports supplying concrete validation. Financing extends runway, while elevated short interest offers a separate source of potential upside.

Key voices
@cnfinancewatchMEDIUM-HIGHB-1.23@BiopharmIQMEDIUM-HIGHB@PrismMarketViewMEDIUM-HIGHC@MisterInversorMEDIUMC-5.25
“RXRX gained 15% despite a discounted $200M raise, with runway, Sanofi and clinical updates supporting demand.”— @BiopharmIQ ·
BEAR / SKEPTIC2 claims

Bears focus on discounted equity issuance diluting shareholders immediately after positive data. Technical sellers separately argue that broken support and fading price spikes undermine the rally.

Key voices
@InvestmentGuru_MEDIUMC-2.08@jimmyhuliMEDIUMC-2.25@CleaRankLOW-MEDIUMC-1.63@R1chardMaur1ceLOW-MEDIUMC-1.19
“Recursion priced a $200M underwritten Class A share offering at $3.25.”— @InvestmentGuru_ ·
Hypotheses13direction · basis · magnitude · supporters — NEW = first seen this week
▲Recursion could become a leading AI drug-discovery infrastructure platform as accelerating biotechnology adoption expands its addressable market and strategic relevance.
bullfundamentallarge if true~40d horizon⚠ single-author-15.1% since 2026-10-10
@cnfinancewatchMEDIUM-HIGHB-1.233s · insight@MisterInversorMEDIUMC-5.255s@harry03994688LOW-MEDIUMA-0.161s · insight
▲RXRX could deliver tenfold investment returns over five years as operating progress supports an aggressive biotechnology growth valuation thesis.
bullfundamentalextreme if true~1825d horizon⚠ single-author-15.1% since 2026-10-09
@DustinHuntwnMEDIUMC-3.753s@Gobbb111LOW-MEDIUMC-0.711s
▲Sanofi's option exercise on a potential first-in-class immunology candidate is a positive collaboration milestone for Recursion's drug-discovery platform.
bullcatalystmedium if true~10d horizonNEWthin-11.1% since 2026-10-15
@InvestmentGuru_MEDIUMC-2.081s@PrismMarketViewMEDIUM-HIGHC1s@BiopharmIQMEDIUM-HIGHB1s
▲Reported favorable clinical study results provide a positive near-term RXRX catalyst, although the supplied accounts lack trial metrics and detailed endpoints.
bullcatalystmedium if true~10d horizonNEWthin-11.1% since 2026-10-15
@PrismMarketViewMEDIUM-HIGHC1s@BiopharmIQMEDIUM-HIGHB1s@OptimalinvestmeLOW-MEDIUMC-2.281s
▼Recursion's discounted equity offering dilutes existing shareholders and creates a financing overhang immediately after favorable company developments lifted investor interest.
bearmechanicsmedium if true~20d horizonNEWthin-11.1% since 2026-10-15
@InvestmentGuru_MEDIUMC-2.081s@CleaRankLOW-MEDIUMC-1.631s@jimmyhuliMEDIUMC-2.251s
▲The equity financing extends Recursion's cash runway, supporting continued development activity and helping investors absorb the immediate dilution burden.
bullmechanicsmedium if true~20d horizonNEWthin⚠ single-author-11.1% since 2026-10-15
@BiopharmIQMEDIUM-HIGHB1s@CleaRankLOW-MEDIUMC-1.631s
▲Reported oversubscription of an RXRX-related transaction signals investor demand and supports a constructive interpretation of the company's financing reception.
bullmechanicssmall if true~10d horizonNEWthin⚠ single-author-11.1% since 2026-10-15
@FloridaHokie20LOW-MEDIUMC+0.201s
▲Morgan Stanley's higher RXRX price target offers incremental valuation support, although its unchanged Equal Weight rating stops short of a bullish upgrade.
bullcatalystsmall if true~10d horizonNEWthin⚠ single-author+6.9% since 2026-10-16
@zohmbasticMEDIUMC-2.941s
▲The announced Biohub partnership is a positive AI-biology sector catalyst for RXRX sentiment, without establishing direct company participation or revenue.
bullcatalystsmall if true~10d horizonthin⚠ single-author-15.1% since 2026-10-09
@OracleNYSEMEDIUMC+0.831s
▲Elevated short interest could amplify RXRX upside through squeeze pressure as enthusiasm for an AI-enabled biotechnology turnaround attracts buyers.
bullpositioninglarge if true~15d horizonthin⚠ single-author-15.1% since 2026-10-10
@harry03994688LOW-MEDIUMA-0.161s · insight@zohmbasticMEDIUMC-2.941s
▼RXRX's support break and the apparent end of repeated price spikes indicate technical deterioration that favors selling to protect gains.
beartechnicalmedium if true~7d horizonNEWthin⚠ single-author-3.4% since 2026-10-13
@R1chardMaur1ceLOW-MEDIUMC-1.191s@TWFeditorLOW-MEDIUMC-1.361s
◆Trimming RXRX near the identified resistance zone reduces exposure after strength without requiring an outright bearish view on the company.
neutraltechnicalsmall if true~5d horizonNEWthin⚠ single-author-11.1% since 2026-10-15
@zohmbasticMEDIUMC-2.941s
◆A single author's unsupported year-end RXRX price target promotes substantial upside without identifying a valuation framework or a specific delivery catalyst.
flagfundamentalextreme if true~76d horizonNEWthin⚠ single-author-11.1% since 2026-10-15
@FloridaHokie20LOW-MEDIUMC+0.201s
Direct calls3authors taking explicit directional positions
@FloridaHokie20LOW-MEDIUMC+0.20
Targets $7 for RXRX before year-end.
@zohmbasticMEDIUMC-2.94
Trims RXRX near the 4.20-4.25 resistance zone.
@R1chardMaur1ceLOW-MEDIUMC-1.19
Sells RXRX after a support break to preserve remaining gains.
Sellside activity1
Morgan Stanley pt_raise PT 5.9 (from 5.3)Raised the price target to $5.90 from $5.30 while retaining Equal Weight.
via @zohmbastic
News / data points5discrete events + data quoted by authors
@BiopharmIQMEDIUM-HIGHB
RXRX gained 15% despite a discounted $200M raise, supported by runway, Sanofi and clinical updates.
2026-10-15-11.1% since
@PrismMarketViewMEDIUM-HIGHC
Reports a $200M offering alongside favorable study data and a Sanofi milestone.
2026-10-15-11.1% since
@InvestmentGuru_MEDIUMC-2.08
Recursion priced a $200M underwritten Class A share offering at $3.25.
2026-10-15-11.1% since
@zohmbasticMEDIUMC-2.94
Morgan Stanley raised its target to $5.90 from $5.30 and retained Equal Weight.
2026-10-16+6.9% since
@OracleNYSEMEDIUMC+0.83
White House agencies announced a $1.8B Biohub partnership for AI-ready biological data; direct RXRX participation is unspecified.
2026-10-09-15.1% since
Position disclosures1skin in the game
@InvestmentGuru_MEDIUMC-2.08
Discloses long-term holdings among biotech watchlist names; RXRX ownership is not explicitly established.
Desk readconvergence assessment
Bullish convergence spans platform potential, Sanofi validation and clinical updates, but repeated basket promotion supplies less independent evidence: cnfinancewatch advances the platform thesis in three posts and DustinHuntwn repeats tenfold upside across three posts, with every times_repeated field equal to 1. Bullish reporting includes MEDIUM-HIGH sources, while bearish voices are MEDIUM or LOW-MEDIUM; negative trader_score_20 readings weaken both camps, including DustinHuntwn at -2.85, cnfinancewatch at -1.1, InvestmentGuru_ at -1.81 and jimmyhuli at -2.25. Quantified clinical results, disclosed Sanofi economics and financing absorption would determine whether validation outweighs dilution; the prior hypotheses are unscored and the ticker is absent from the current book.
Options inteloptions-surface reads · latest available day per source
metricreadingcontext
IV — ATM 30d93% mid · 40 pctile own 1yIV/HV 0.98×
Skew — 25Δ RR 30d+0.043 12 pctile own 1yputs bid vs calls (downside bid)
Net dealer OI (NDOI)+1.41 elevated5-session Δ -0.73 (as of 2026-07-16)
OI alarmquietlast alarm 2026-05-29 (z=3.4)
Sentiment — last 14 days
daily mean sentiment, 2026-10-03 → 2026-10-16 · now -0.05 (−1 bearish … +1 bullish)
Who spoke53
authorgradetrader scoresignalsmean sent
@MisterInversorC-5.2521+0.54
@cnfinancewatchB-1.2314+0.32
@beach_tradesC-2.976+0.34
@DustinHuntwnC-3.755+0.52
@zohmbasticC-2.945+0.19
@BiopharmIQB·4+0.29
@InvestmentGuru_C-2.084+0.26
@VoxVex000B-3.263+0.75
@FloridaHokie20C+0.203+0.55
@PrismMarketViewC·2+0.15
@TheBronxVikingC-2.432+0.57
@TautilasC-0.322+0.35
@R1chardMaur1ceC-1.192-0.03
@eugeniodevezeC-3.142+0.28
@MartinShkreliB+0.882-0.90
@OptionsFlowBossC·2+0.40
@DeNebulordC-0.552+0.20
@42tradersB-1.222+0.45
@TalkMarketsC·2+0.15
@equityddC-1.082+0.10
@SVTrivoC-0.521+0.45
@kkernttbC-0.951+0.35
@mark_to_mktC-0.671+0.65
@ArtofSpecuyckyB-3.391+0.65
@ConnorJBates_B-0.781+0.50
Recent signals30of 120 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-10-16@TWFeditor-0.55Says RXRX's month of price spikes has ended.+6.9%
2026-10-16@MisterInversor+0.50Argues three biotech names have massive addressable markets if execution succeeds.+6.9%
2026-10-16@DustinHuntwn+0.10Biotech stock list without an explicit trade action or detailed thesis.+6.9%
2026-10-16@zohmbastic+0.20Morgan Stanley raised RXRX's target to $5.90 from $5.30 and retained Equal Weight.+6.9%
2026-10-16@jimmyhuli-0.50Reports RXRX issuing shares immediately after positive data.+6.9%
2026-10-15@Optimalinvestme+0.45States RXRX has a successful clinical study, but supplies no trial metrics or named source.-11.1%
2026-10-15@equitydd+0.00Lists stocks making large moves without specifying direction in text.-11.1%
2026-10-15@zohmbastic+0.20Notes substantial RXRX volume arriving near the close.-11.1%
2026-10-15@thesetupfactory+0.40Highlights a strong intraday burst in RXRX.-11.1%
2026-10-15@InvestmentGuru_-0.30Recursion priced a $200M underwritten Class A share offering at $3.25.-11.1%
2026-10-15@InvestmentGuru_+0.45Recursion says Sanofi optioned a potential first-in-class immunology candidate from their collaboration.-11.1%
2026-10-15@cnfinancewatch+0.55RXRX rose 17% intraday and helped activate the biotech sector.-11.1%
2026-10-15@BiopharmIQ+0.45RXRX gained 15% despite a discounted $200M raise, supported by runway, Sanofi and clinical updates.-11.1%
2026-10-15@BiopharmIQ+0.35The tweet lists large opening biotech moves and upcoming Phase 3 catalysts.-11.1%
2026-10-15@BiopharmIQ+0.35The post lists major opening biotech gains and the news associated with each move.-11.1%
2026-10-15@zohmbastic+0.00Highlights RXRX's high short interest.-11.1%
2026-10-15@FloridaHokie20+0.45Recaps RXRX reversing from down 10% to up 14%.-11.1%
2026-10-15@zohmbastic+0.30Trimming some RXRX near the 4.20-4.25 resistance zone. — Explicit present-tense trim at a specified price zone.-11.1%
2026-10-15@PrismMarketView+0.20Reports a $200M offering alongside favorable study data and a Sanofi milestone.-11.1%
2026-10-15@DustinHuntwn+0.05Bare promotional biotech list with no explicit trade action or thesis.-11.1%
2026-10-15@DustinHuntwn+0.90Five-year bullish biotech thesis identifies RXRX as a potential tenfold winner.-11.1%
2026-10-15@zohmbastic+0.25Notes an RXRX recovery while also tagging SNY without explaining its role.-11.1%
2026-10-15@CleaRank-0.25RXRX sold $200M of discounted shares, causing dilution while extending its runway.-11.1%
2026-10-15@FloridaHokie20+0.75Expect RXRX to reach $7 before year-end. — Gives a bullish forward price target and deadline for RXRX.-11.1%
2026-10-15@FloridaHokie20+0.45Emphasizes that an RXRX-related transaction was oversubscribed.-11.1%
2026-10-14@MisterInversor+0.75Forecasts a century of biotechnology progress within five years and identifies five beneficiaries.-1.1%
2026-10-14@StockSwingAlert+0.40References another person's past RXRX winner while criticizing their record.-1.1%
2026-10-14@MisterInversor+0.50Links worsening population health to a bullish long-term healthcare innovation basket.-1.1%
2026-10-13@R1chardMaur1ce-0.70Sell RXRX after its support break to protect remaining gains. — Is selling RXRX because it lost support and the author wants to preserve gains.-3.4%
2026-10-13@InversorSensei+0.55Says now is the moment when RXRX could rise.-3.4%

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.